D961H Sachet 20 mg + D961H HPMC capsule 20 mg
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence Study
Conditions
Bioequivalence Study
Trial Timeline
May 1, 2012 → Jun 1, 2012
NCT ID
NCT01595425About D961H Sachet 20 mg + D961H HPMC capsule 20 mg
D961H Sachet 20 mg + D961H HPMC capsule 20 mg is a phase 1 stage product being developed by AstraZeneca for Bioequivalence Study. The current trial status is completed. This product is registered under clinical trial identifier NCT01595425. Target conditions include Bioequivalence Study.
What happened to similar drugs?
1 of 1 similar drugs in Bioequivalence Study were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01964131 | Phase 1 | Completed |
| NCT01595425 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence Study